Details for Patent: 8,329,159

Title:	Hepatitis C virus inhibitors
Abstract:	The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Inventor(s):	Belema; Makonen (North Haven, CT), Nguyen; Van N. (New Britain, CT)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Filing Date:	Aug 08, 2007
Application Number:	11/835,462
Claims:	1. A compound which is methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S) -2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol- -5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpr- opyl)carbamate; or a pharmaceutically acceptable salt thereof. 2. A compound which is (1R,1'R)-2,2'-(4,4'-biphenyldiylbis(1H -imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl))bis(N,N-dimethyl-2-oxo-1-phe- nylethanamine); or a pharmaceutically acceptable salt thereof. 3. A compound which is methyl ((1S)-2-((2S)-2-(5-(4'-(2-((2S)-1-((2R)-2-(diethylamino)-2-phenylacetyl)-- 2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl) -1H-imidazol-2-yl)-1-pyrrolidinyl)-1-methyl-2-oxoethyl)carbamate; or a pharmaceutically acceptable salt thereof. 4. A compound which is methyl ((1R)-2-oxo-1-phenyl-2-((2S)-2-(5-(4'-(2-((2S)-1-((2R)-tetrahydro-2-furan- ylcarbonyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-- yl)-1-pyrrolidinyl)ethyl)carbamate; or a pharmaceutically acceptable salt thereof. 5. A compound which is methyl ((1R)-2-((2S)-2-(5-(4'-(2-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)- -2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrro- lidinyl)-2-oxo-1-phenylethyl)carbamate; or a pharmaceutically acceptable salt thereof. 6. A compound which is dimethyl (4,4'-biphenyldiylbis(1H -imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl((1R)-2-oxo-1-phenyl-2,1-ethan- ediyl)))biscarbamate; or a pharmaceutically acceptable salt thereof. 7. A compound which is (1R)--N,N-dimethyl-2-oxo-1-phenyl-2-((2S) -2-(5-(4'-(2-((2S)-1-((2R)-tetrahydro-2-furanylcarbonyl)-2-pyrrolidinyl)-- 1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)ethanamin- e; or a pharmaceutically acceptable salt thereof.